Sorted By:

Relevance


What Do Clinical Pathways Mean for Treatment Options?

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/what-do-clinical-pathways-mean-for-treatment-options

PhRMA and BIO Initiate Litigation to Challenge Unconstitutional Provisions of Nevada’s SB 539

PhRMA  |  Press Release

About BIOBIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
https://www.phrma.org/phrma-bio-release

Clarity around anti-kickback statute needed to promote innovative payment arrangements

PhRMA  |  Blog Post

Providing clear safe harbor protection to RBCs can encourage the uptake of these innovative payment arrangements and help advance our movement toward a health care system that better recognizes value.
http://catalyst.phrma.org/clarity-around-anti-kickback-statute

Medicine Spending Relatively Stable Following Increased Regulatory Data Protection in Canada and Japan

PhRMA  |  Blog Post

The report does state that “there could be many explanations for these results….However, the evidence suggest that those concerned about access to medicines and the financial stability of public healthcare systems should focus their attention on policies other than RDP for medicines.
http://catalyst.phrma.org/medicine-spending-relatively-stable-following-increased-regulatory-data-protection-in-canada-and-japan

8 Reasons to Celebrate World Kidney Day

PhRMA  |  Blog Post

 They changed the course of my life forever.For all these reasons and more, I celebrate World Kidney Day and National Kidney Month.
http://catalyst.phrma.org/8-reasons-to-celebrate-world-kidney-day

Vermont's 2016 Exchange Plans

PhRMA  |  Fact Sheet

States can continue to protect patients in their state through the following actions: Enforcing non-discrimination requirements, which apply to benefit design and provider networks; Establishing stronger rules regarding exceptions and appeals processes, which help enrollees get the medicines and care their doctors recommend; and Enhancing the state's marketplace website or advocating for a Healthcare.gov page that allows for easier plan comparisons, including searchable formularies and estimates of total out-of-pocket costs.
https://www.phrma.org/fact-sheet/vermont-s-2016-exchange-plans

PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis

PhRMA  |  Blog Post

Using PDMPs has proven to be an effective way to identify potential doctor shoppers and to foster appropriate prescribing but only when they are used and provide relevant data.
http://catalyst.phrma.org/phrma-supports-presidents-commissions-holistic-approach-on-opioid-crisis

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

PhRMA  |  Blog Post

America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property protections, public sector investments in education and basic sciences, and a reliable rule of law
http://catalyst.phrma.org/icymi-ubl-weighs-in-on-how-fair-trade-protects-us-biopharmaceutical-innovation

The Pacira Case Study: Patients are better served when health care professionals have the most accurate and up-to-date medical information

PhRMA  |  Blog Post

It is critical to modernize the FDA’s regulatory framework not only to make more comprehensive and up-to-date information available to health care providers and payers, but also to eliminate any confusion resulting from the recent and ongoing legal proceedings and adhere to the rulings in cases such as Caronia and Amarin.
http://catalyst.phrma.org/the-pacira-case-study-patients-are-better-served-when-health-care-professionals-have-the-most-accurate-and-up-to-date-medical-information

Together - Cancer

PhRMA  |  Video

See how a two-week old targeted therapy drug has now created a link between them. 
https://www.phrma.org/video/together-cancer

Guest Contributor: Debra of America on Epidermolysis Bullosa

PhRMA  |  Blog Post

We want to be recognized for living through challenges that others may not face. 
http://catalyst.phrma.org/guest-contributor-debra-of-america-on-epidermolysis-bullosa

PhRMA Statement on Rep. Eshoo’s Follow-on Biologics Bill

PhRMA  |  Press Release

“Current testing methods cannot detect all of the differences between follow-on biologics and the reference biologic that may adversely impact patient health.
https://www.phrma.org/press-release/phrma-statement-on-rep-eshoo-s-follow-on-biologics-bill

Matt and Jamie share their stories in new “From Hope to Cures” ads

PhRMA  |  Blog Post

Thanks to the perseverance of biopharmaceutical researchers and scientists, patients like Matt and Jamie continue to live longer, healthier lives.
http://catalyst.phrma.org/matt-and-jamie-share-their-stories-in-new-from-hope-to-cures-ads

Four Facts on Why Drug Importation is Bad for Patients

PhRMA  |  Fact Sheet

Due to the U.S. Food and Drug Administration’s (FDA) comprehensive drug approval process, medicines on the U.S. market are widely regarded as the safest in the world. The U.S.’s relatively closed distribution system plays a critical role in helping to keep the global proliferation of counterfeit ...
https://www.phrma.org/fact-sheet/four-facts-on-why-drug-importation-is-bad-for-patients

ICYMI - The Economists’ Voice: Are biopharmaceutical budget caps good public policy?

PhRMA  |  Blog Post

If newer, less toxic, but potentially more expensive cancer medicines can keep patients out of the hospital, give them the option to work or go about daily activities or spend quality time with loved ones while undergoing treatment, shouldn’t we allocate a greater proportion of health care dollars to these advances? 
http://catalyst.phrma.org/icymi-the-economists-voice-are-biopharmaceutical-budget-caps-good-public-policy

PhRMA Statement on AARP-White House Press Conference

PhRMA  |  Press Release

PhRMA companies are leading the way in the search for new cures.
https://www.phrma.org/press-release/phrma-statement-on-aarp-white-house-press-conference

North Dakota's 2016 Exchange Plans

PhRMA  |  Fact Sheet

States can continue to protect patients in their state through the following actions: Enforcing non-discrimination requirements, which apply to benefit design and provider networks; Establishing stronger rules regarding exceptions and appeals processes, which help enrollees get the medicines and care their doctors recommend; and Enhancing the state's marketplace website or advocating for a Healthcare.gov page that allows for easier plan comparisons, including searchable formularies and estimates of total out-of-pocket costs.
https://www.phrma.org/fact-sheet/north-dakota-s-2016-exchange-plans

Taking the Necessary Steps to Make the Cancer Moonshot Work

From Hope To Cures  |  From Our Network

Congressman Fred Upton has made developing medical treatments a major focus and his commitment to engaging policymakers and elevating the conversation beyond Capitol Hill is admirable.
http://www.fromhopetocures.org/taking-the-necessary-steps-to-make-the-cancer-moonshot-work

Point of Sale Rebate Analysis in the Commercial Market

PhRMA  |  Report

Under this approach, a member using brand medications has the same out-of-pocket cost for the prescriptions whether a rebate was received. 
https://www.phrma.org/report/point-of-sale-rebate-analysis-in-the-commercial-market

World IP Day: Celebrating the protections that allow innovation to thrive

PhRMA  |  Blog Post

This World IP Day, we hope America continues their commitment to the life sciences industry and the advancement of new treatments.
http://catalyst.phrma.org/world-ip-day-celebrating-the-protections-that-allow-innovation-to-thrive

PhRMA Statement on Clinical Trials and Bad Pharma

PhRMA  |  Press Release

According to the National Science Foundation, nearly 20 percent of all domestic R&D can be attributed to the biopharmaceutical sector – the single largest share of all U.S. business R&D.
https://www.phrma.org/press-release/phrma-statement-on-clinical-trials-and-bad-pharma

James M. "Mit" Spears Named Executive Vice President & General Counsel

PhRMA  |  Press Release

PhRMA companies are leading the way in the search for new cures.
https://www.phrma.org/press-release/james-m-mit-spears-named-executive-vice-president-and-general-counsel

Personalized Medicines Are Benefitting Patients Across Many Different Diseases

Chartpack  |  From Our Network

Across a variety of therapeutic areas, an increasing number of treatments are personalized, including medicines for cancer, psychological disorders, infectious diseases, and cardiac diseases, among many others. 
http://chartpack.phrma.org/personal-medicines-in-development-chartpack/a-new-treatment-paradigm/personalized-medicines-are-benefitting-patients-across-many-different-diseases

New Study: Policy Environment Has a Significant Impact on Biopharmaceutical Investment

PhRMA  |  Blog Post


http://catalyst.phrma.org/new-study-policy-environment-has-a-significant-impact-on-biopharmaceutical-investment

4 Facts on Why Drug Importation is Bad for Patients

PhRMA  |  Fact Sheet

Counterfeit drug trafficking is a multibillion dollar business that threatens the health and well-being of patients. The World Health Organization estimates 10 percent of medicines worldwide are counterfeit, including up to half of the drugs consumed in developing nations. Fortunately for America...
https://www.phrma.org/fact-sheet/4-facts-on-why-drug-importation-is-bad-for-patients

You have reviewed the first 225 results out of 2148. Each page contains 25 results. You're on page 9.

prev 7 8 9 10 11 12 next